News about Global Pharma

PharmaLytica 2024 Commences Successfully in Hyderabad

Informa Markets India has announced the successful commencement of the 10th edition of PharmaLytica 2024 at HITEX, Hyderabad.

Global Pharma | 31/05/2024 | By Aishwarya |  1064

Nxera Pharma to Receive USD 4.6 Million from Centessa

Nxera Pharma has been expecting to receive USD 4.6 million in milestone payments from Centessa Pharmaceuticals under a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750.

Global Pharma | 30/05/2024 | By Aishwarya |  572

H.E.L Group Expands its Sales Newtowk with Addition of Two Specialist Distributors

H.E.L Group (H.E.L) has expanded its global sales network with the appointment of two distributors: Paralab and ProAnalytics.

Global Pharma | 30/05/2024 | By Aishwarya |  786

Merck Announces Acquisition of EyeBio

Merck has signed a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

Global Pharma | 30/05/2024 | By Aishwarya |  751

HanAll Biopharma and Turn Bio to Develop Novel Treatments for Eye and Ear Diseases

HanAll Biopharma Co., Ltd. has signed an exclusive licensing deal with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.

Global Pharma | 29/05/2024 | By Aishwarya |  2712

Reddy Pharma Iberia and Theranica Launch Nerivio in Spain

Dr. Reddy's Laboratories Ltd. and its subsidiaries have introduced Nerivio in Spain through its step-down subsidiary, Reddy Pharma Iberia S.A.

Global Pharma | 29/05/2024 | By Aishwarya |  1159

Gerresheimer Expands Capacities for Medical Systems in USA

Gerresheimer is significantly expanding its production capacities for medical systems such as inhalers and autoinjectors in the United States.

Global Pharma | 28/05/2024 | By Manvi |  426

AcariaHealth Opens Modern Specialty Pharmacy Facility in Chesterfield, Missouri

The facility is the home of Foundation Care, one of AcariaHealth's Centers of Excellence devoted to providing personalized care to patients with rare and chronic conditions.

Global Pharma | 28/05/2024 | By Manvi |  457

Novartis Presents Interim Analysis of atrasentan Phase III Data

Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).

Global Pharma | 28/05/2024 | By Aishwarya |  826

Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok

Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.

Global Pharma | 28/05/2024 | By Aishwarya |  958